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This is an official
CDC HEALTH ADVISORY
False-positive Results with a Commercially-Available West Nile Virus IgM ELISA 
Kit
The Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and state health departments are 
investigating an increase in false-positive test results obtained with a commercially-available West Nile virus immunoglobulin M capture 
enzyme-linked immunosorbent assay (WNV IgM capture ELISA). On October 8, 2008, Inverness Medical (Princeton, NJ), the 
manufacturer of the implicated assays, voluntarily recalled two lots of their PanBio WNV IgM capture ELISA kit. One lot (#07262) was 
only distributed in Canada. The other lot (#08118) was distributed from July-September 2008 to four laboratories in the United States. The 
laboratories that used the recalled test kit include ViroMed (Minnetonka, MN), Meritcare Health System (Fargo, ND), Pennsylvania 
Department of Health (Exton, PA), and Baylor University Medical Center (Dallas, TX). Based on the investigation to date, this increase in 
false-positive results appears to be limited to these two lots of the PanBio kit. CDC and FDA will continue to monitor and evaluate any 
additional reports of false-positive tests that may have resulted from previous lots.
As background, there are four FDA-cleared WNV IgM ELISA kits from different manufacturers commercially-available in the U.S. 
According to the package inserts, all of these kits are indicated for use on serum to aid in the presumptive laboratory diagnosis of WNV 
infection in patients with clinical symptoms of meningitis or encephalitis. The package inserts also state that all positive results obtained 
with any of the commercially-available WNV test kits should be confirmed by additional testing at a state health department laboratory or 
CDC. Public health practitioners, healthcare providers and clinical laboratories are reminded to consider the intended use and limitations of 
these kits when requesting WNV testing and interpreting the results.
The testing laboratories specified above will work with CDC and state and local health departments to notify hospitals or healthcare 
providers who submitted specimens that tested positive between July and September 2008 using the recalled PanBio kit. If the original 
specimen is still available, it will be retested at a state public health laboratory or CDC using a different WNV IgM assay. Healthcare 
providers will be notified of the results. If the original specimen is not available, health departments will work with healthcare providers to 
decide if a new serum specimen should be obtained for WNV testing. As the investigation proceeds, the provisional number of WNV 
disease cases reported to CDC for 2008 will be adjusted, with information available at www.cdc.gov/westnile.
False-positive test results that occurred between July and September 2008 may have led to an incorrect diagnosis in some patients. If the 
patient is still experiencing symptoms, additional evaluation and alternative diagnoses should be considered. State health departments can 
help healthcare providers decide if a new serum specimen should be obtained to test for WNV or another etiology.
For more information about false-positive WNV tests, refer to http://"
http://www.cdc.gov/ncidod/dvbid/westnile/wnv_DiagnosticsUpdate.html. For more information on individual specimens affected by this 
commercial test recall, please contact your state health department.
The Centers fo r Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and in juries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships w ith local, national and international
organizations.
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